5 Key Takeaways on Most Favored Nations Pricing From MJH Life Sciences Webinar

Most Favored Nation (MFN) pricing represents a major shift in U.S. drug policy. While intended to make medications more affordable, experts during an MFN 2025 webinar warned it could slow innovation, especially in oncology, and disrupt the balance of the healthcare system. Legal challenges, interactions with the IRA and 340B programs and how insurance covers medications will shape its impact on patients, payers and drug companies.